Member Info for ForFXSake

I still doesn't make sense to me that the Asian partner is no longer interested. The only reason I can think of is that they couldn't agree on price.

If it was either because they didn't think the product could work or they didn't like who they were dealing with, then both of those reasons no longer stand.

It's probably dropped back to 65p now cos we've rocked up :0)

I could just about suffer 65p.

Looks like the action happened before phase 1 commenced as well.

Hope this link works:

https://www.google.co.uk/url?sa=t&source=web&rct=j&url=https://www.redxpharma.com/wp-content/uploads/2018/12/Redx-signs-out-licensing-agreement-with-AstraZeneca.pdf&ved=2ahUKEwjmr8mQib70AhVGUcAKHSHMCvsQFnoECAMQAQ&usg=AOvVaw2gOf6k69YUT4okAJEhfg9T

Beginning to think the broker is still on furlough.

Thanks OBW.

Could be an exciting result then.

Thanks for clarifying that Soup

Good Afternoon, rather.

Morning OBW

Yes, it would be nice to know a bit more detail in the near future. I'm interested to know why it will take 12 months to get to phase 1 readiness.

The sample manufacturing design should really be handled by a CMO with guidance from Nuformix, so I would have thought there should be little by way of certification processing required (CMO should already have the necessaries). In fact, I'm surprised that someone hasn't already been approached provisionally .

As far as recruitment goes, if everything is outsourced then they should need too many news bods over and above a new CEO.

So other than documentation, what needs to be done?

If it is further testing (i.e. toxicology) then does that pose a risk if it is currently unknown?

One thing I did find odd about yesterday's interview was that, towards the end of the video, AR started to talk about now testing NXP002 as part of '****tail of drugs'.

He seemed to say that they were now planning to test NXP002 alongside pirfenidone and nintedanib but he didn't seem to acknowledge the previous test results that were announced on 2nd March 2020.

It makes me wonder if some of the tests done in the past were worth the effort if they are having to be done again.

I wonder if that additional patent potential is linked to COVID-19?

I think the Asian deal is dead though. I don't see why they would want to wait another year for phase 1 readiness when someone else could enter the mix.

I suspect that deal was killed in early 2020 and was the reason for the exodus. AB was perhaps just looking to see if it could be rekindled. However, I suspect that was no go as AR wouldn't be planning that far ahead if it looked like we were going to get taken out.

Just hope they are not considering taking this too far forward without an agreement. Could get costly with placings.

I like this Riddell guy. His finger seems to be on the pulse

So January still the target for the last test data and further patent potential.

12 months until phase 1 ready though (so not quite 9p yet)

Sounds like they are going to expand the team.

...and as if by magic:

https://www.youtube.com/watch?v=0Gpm_miNC_A

If the true value is not reflected based on de-risking then small companies would find it difficult to raise interest from investors to take drugs forward.

If trading volume was the only gauge of value then they would be open to price manipulation by potential predators who would rather see the company go under than pay a fair price for the IP.

Surely that would be wide-open to fraudulent abuse?

I agree with thecstatement that value should have been added here simply from the de-risking. According to the company broker, the value of being phase 1 ready with no deal is circa 9p per share.

To say that there is no value from the de-risking of a drug moving from unproven pre-clinical to phase 1 ready is like saying that there is no de-risking of a drug at any phase change. You might as well say it is worthless until it passes phase 3.

Value has been added regardless of trading volumes and should be reflected in the price as soon as possible. That is unless, the RNS has been sent too early and NXP002 can still fail on durability. My assumption from yesterday's RNS was that that is extremely unlikely.

If the RNS was released too early then why? Surely it wasn't just a smokescreen to deflect attention away from the vague statement which implies that the durability test deadline has moved beyond January? That would be a tactic I would expect from the old guard! Especially if that test is critical to phase 1 readiness.

Ideally, the BoD should clarify the significance of the need to release the RNS following the interview (which said roughly the same), at least to highlight the significance of the final test and confirm or deny any further slippage to the final test results deadline.

I doubt that's going to happen though.

Hard to believe that positive NXP002 data is worth all of 0.1p on every share.

Someone's taking the p*** here.

I read in the media yesterday that the Taliban were looking to enter the market supplying cannabis to Western companies. Rumour had it that they were negotiating with an Australian company.

Thinking about it, it could be a great opportunity for Ebers to secure a stable supply of raw materials for their future ventures. Given Topalcsky's track record of closing deals with foreign companies, perhaps he would be an ideal choice to send over to Kabul, as chief negotiator.

500k traded by 10.25 and a bid of 1.6p the day after we receive positive data for NXP002 is a stark contrast to the receipt of NXP001 data in 2019.

Alot of damage has been done by the false promises and failed deals of the Gooding years. It looks like there is still hard work ahead for those who remain.

Let's hope Mars is right and enquiries are being made.

"For me it was AB signing off from a job well done."

What you gonna do when she's gone Goup? I hope you've got a signed photo to remember her by :0)